Answers are grounded in this paper and cite their sources.
BACKGROUND: TR-700 is the active moiety of TR-701 (DA-7157), a new oral/intravenous oxazolidinone prodrug. We examined its activity against linezolid-susceptible and -resistant staphylococci and enterococci. METHODS: MICs were determined by the CLSI agar dilution method. RESULTS: MICs of TR-700 were tightly clustered around 0.5 mg/L for linezolid-susceptible staphylococci and enterococci compared with 2 mg/L for linezolid. MICs for 52 linezolid-resistant isolates were raised, but only exceeded 4 mg/L for two Enterococcus faecium isolates homozygous for the G2576T 23S rRNA mutation and for one with an unknown mechanism of linezolid resistance. CONCLUSIONS: TR-700 is 4- to 16-fold more active than linezolid and overcame most linezolid resistance in vitro.
No takes yet. Share an insight, caveat, or question.
Livermore et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: